BIOMARIN PHARMACEUTICAL INC

20 February, 2025

BioMarin Provides Insights on Q4 2024 Earnings and Future Outlook During February Conference Call

BioMarin Pharmaceutical Inc. recently held its Q4 2024 earnings conference call on February 19, 2025, showcasing insights from key executives like CEO Alexander Hardy and CFO Brian Mueller. The event ...
Read More

17 February, 2025

BioMarin's Earnings Estimates Rise Amidst Decline in Stock Value, Highlighting Analyst Confidence and Consistent Performance

BioMarin Pharmaceutical Inc. is currently facing a challenging market environment, with its share price down 28.4% over the past year. However, recent earnings estimates have shown some resilience, as...
Read More

16 February, 2025

BioMarin's Earnings Estimates Rise Amidst Decline in Stock Value, Highlighting Analyst Confidence and Consistent Performance

BioMarin Pharmaceutical Inc. is currently facing a challenging market environment, with its share price down 28.4% over the past year. However, recent earnings estimates have shown some resilience, as...
Read More

15 February, 2025

BioMarin Sees Slight Increase in 2024 Earnings Estimates Despite Recent Stock Decline and Strong Performance History

BioMarin Pharmaceutical has shown resilience in its earnings forecasts for 2024, with estimates edging up from $3.28 to $3.29 per share. For 2025, estimates have slightly decreased from $4.02 to $4.01...
Read More